Literature DB >> 3300079

Antigenicity and immunogenicity of domains of the human immunodeficiency virus (HIV) envelope polypeptide expressed in the yeast Saccharomyces cerevisiae.

P J Barr, K S Steimer, E A Sabin, D Parkes, C George-Nascimento, J C Stephans, M A Powers, A Gyenes, G A Van Nest, E T Miller.   

Abstract

Expression vectors were constructed for the production of various domains of the envelope gene product of the SF-2 isolate of human immunodeficiency virus (HIV) in the yeast Saccharomyces cerevisiae. Serum specimens from HIV seropositive blood donors reacted in immunoblot assays with recombinant polypeptides from both the gp120 and gp41 coding regions of env. Polypeptides from both domains were purified and injected into experimental animals. Antibodies raised in rabbits to env-2, a recombinant polypeptide representing the majority of the protein moiety of gp120, reacted with fully glycosylated native gp120 of HIV-SF2 virions. In addition, these env-2 antisera showed reactivity with viral gp120 of divergent HIV isolates. A 121 amino acid polypeptide (env-5), representing the region of gp41 stretching between the two hydrophobic domains of the protein, elicited antibodies in rabbits that reacted with glycosylated, native gp41. Thus, selected domains of the HIV env gene expressed in genetically engineered yeast, are recognized by sera from HIV infected humans, elicit antibodies that react with native HIV glycoproteins and provide a source of envelope antigens for evaluation as potential subunit vaccines for HIV.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3300079     DOI: 10.1016/0264-410x(87)90053-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles.

Authors:  Bao-Zhong Wang; Weimin Liu; Sang-Moo Kang; Munir Alam; Chunzi Huang; Ling Ye; Yuliang Sun; Yingying Li; Denise L Kothe; Peter Pushko; Terje Dokland; Barton F Haynes; Gale Smith; Beatrice H Hahn; Richard W Compans
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

2.  Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro.

Authors:  J F Krowka; D P Stites; S Jain; K S Steimer; C George-Nascimento; A Gyenes; P J Barr; H Hollander; A R Moss; J M Homsy
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

3.  Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization.

Authors:  C Cheng-Mayer; J Homsy; L A Evans; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

4.  Vaccinia virus recombinants expressing chimeric proteins of human immunodeficiency virus and gamma interferon are attenuated for nude mice.

Authors:  L D Giavedoni; L Jones; M B Gardner; H L Gibson; C T Ng; P J Barr; T Yilma
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

5.  Priming of CD4+ T cells specific for conserved regions of human immunodeficiency virus glycoprotein gp120 in humans immunized with a recombinant envelope protein.

Authors:  S Abrignani; D Montagna; M Jeannet; J Wintsch; N L Haigwood; J R Shuster; K S Steimer; A Cruchaud; T Staehelin
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

6.  Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Harold Legg; Elaine Kan; Anne Fong; Stephen R Coates; Louisa Leung; Mark Wininger; John J Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  Identification of human immunodeficiency virus (HIV) envelope type-specific T helper cells in an HIV-infected individual.

Authors:  C M Walker; K S Steimer; K L Rosenthal; J A Levy
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

8.  Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Elaine Kan; Michael Vajdy; Ying Lian; Susan Hilt; Loic Martin; Claudio Vita; Ping Zhu; Kenneth H Roux; Lucia Vojtech; David C Montefiori; John Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Characterization of murine polyclonal antisera and monoclonal antibodies generated against intact and denatured human papillomavirus type 1 virions.

Authors:  N Yaegashi; S A Jenison; J M Valentine; M Dunn; L B Taichman; D A Baker; D A Galloway
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

10.  Simian retrovirus-D serotype 1 (SRV-1) envelope glycoproteins gp70 and gp20: expression in yeast cells and identification of specific antibodies in sera from monkeys that recovered from SRV-1 infection.

Authors:  H S Kwang; P J Barr; E A Sabin; S Sujipto; P A Marx; M D Power; I C Bathurst; N C Pedersen
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.